Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation reports developments in surgical robotics for urology, centered on its AQUABEAM and HYDROS Robotic Systems and Aquablation therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia. Company news commonly covers financial results, system sales and procedure trends, commercial execution, pricing and inventory commentary, and investment in its BPH platform technology.
Updates also include product clearances such as FirstAssist AI software, international launch activity for HYDROS, clinical evidence and guideline recognition for Aquablation therapy, investor presentations, and research activity including the WATER IV prostate cancer trial.
PROCEPT BioRobotics (Nasdaq: PRCT) reported two key milestones in its WATER IV prostate cancer program: completion of enrollment in the randomized WATER IV RP study comparing Aquablation therapy with radical prostatectomy, and expanded FDA IDE approval for a second randomized WATER IV AS protocol versus active surveillance.
WATER IV RP has fully enrolled 280 patients, with primary endpoint results expected at the AUA Annual Meeting in spring 2027. WATER IV AS will enroll up to 333 patients and, along with WATER IV RP, will follow men for ten years to assess disease control and quality-of-life outcomes.
PROCEPT BioRobotics (Nasdaq: PRCT) announced that updated American Urological Association (AUA) guidelines strengthen the recommendation for Aquablation therapy as a surgical option for men with BPH and prostate volumes of 30–80 mL. The AUA also recognizes Aquablation may be offered for larger prostates of 80–150 mL.
The update reflects maturing clinical evidence, including randomized trials showing durable urinary symptom and flow improvements through five years across a broad range of prostate sizes. Aquablation is supported by trials against TURP and laser enucleation. Earlier this year, European Association of Urology (EAU) guidelines also issued a strong recommendation for Aquablation.
PROCEPT BioRobotics (Nasdaq: PRCT) announced management will present at three investor conferences in May and June 2026: Bank of America Health Care (May 12, Las Vegas), William Blair Growth Stock (June 2, Chicago) and Truist Med‑Tech (June 16, Boston).
Live webcasts and archived recordings will be available on the company Investors website and will remain accessible for at least 90 days after each event.
PROCEPT BioRobotics (Nasdaq: PRCT) reported Q1 2026 results: $83.1M revenue (+20% YoY), ~12,200 U.S. procedures (+30% YoY), 49 U.S. Hydros system sales, and 65% gross margin. Cash and equivalents totaled approximately $249M. The company confirmed full‑year 2026 revenue guidance of $390–$410M and expects U.S. procedure growth of 39–48%.
Q1 net loss was $31.6M with adjusted EBITDA loss of $18.1M; operating expenses increased to $86.6M.
PROCEPT BioRobotics (Nasdaq: PRCT) will report first quarter 2026 financial results after market close on April 29, 2026. Management will host a conference call at 4:30 p.m. Eastern Time the same day.
Webcast and dial-in registration links are provided for investors and analysts, live audio will be available on the company investor website, and an archived recording will remain available for at least 90 days.
PROCEPT BioRobotics (Nasdaq: PRCT) highlighted the European Association of Urology upgrade of Aquablation therapy to a strong surgical recommendation for benign prostatic hyperplasia (BPH) on March 23, 2026.
The guidelines cite randomized trials (WATER, WATER II, WATER III) and expanded evidence for larger prostate anatomies, and note complementary support from UK NICE for routine NHS use.
PROCEPT BioRobotics (Nasdaq: PRCT) announced the international launch of the HYDROS Robotic System on March 12, 2026, beginning in the UK, with additional international expansion planned in 2026. HYDROS is described as the first AI-enabled robotic platform for Aquablation therapy to treat benign prostatic hyperplasia (BPH).
The system combines AI-interpreted real-time ultrasound, advanced image-guided treatment planning, and robotic precision to deliver personalized, anatomy-specific Aquablation procedures. The company said HYDROS aims to support scalable adoption across care settings while preserving sexual and urinary function, and to expand surgical choice for men living with BPH.
PROCEPT BioRobotics (Nasdaq: PRCT) hosted its 2026 Investor Day outlining a multi-year plan to drive leadership in BPH with Aquablation therapy. Management projects 2026 revenue growth of 27%–33%, 2026 procedure growth of 39%–48%, and 2026 gross margin of 65%, improving to 68%–70% in 2027.
The company expects positive adjusted EBITDA in Q4 2026 and a 2027 adjusted EBITDA gain of $25–30 million. WATER IV prostate cancer trial procedures are expected complete by mid-2026, and more than 125,000 patients have been treated to date.
PROCEPT BioRobotics (Nasdaq: PRCT) reported Q4 2025 revenue of $76.4M, full-year 2025 revenue of $308.1M (+37% YoY) and Q4 procedure volume of ~12,200 (Q4 handpieces ~9,400).
Q4 sold 65 systems, ending U.S. install base 718 systems (+42% YoY). Q4 gross margin 61%; net loss $29.8M. 2026 guidance: revenue $390–$410M, gross margin ~65%, adjusted EBITDA loss $30M–$17M.
PROCEPT BioRobotics (Nasdaq: PRCT) updated timing for its fourth quarter 2025 earnings release and Investor Day due to travel disruptions from inclement weather.
The Company will report Q4 2025 results after market close on Wednesday, February 25, 2026, with a conference call at 4:30 p.m. ET. The in-person Investor Day is rescheduled to Thursday, February 26, 2026, 8:00 a.m. ET at NASDAQ Headquarters in New York City. A live webcast and archived recordings will be available on the Investors section of the company website and replayed for at least 90 days.